Sugi Predict

Sugi Predict / Compounds / SCHEMBL559917

SCHEMBL559917

SCHEMBL559917

O=C(/C=C/c1ccccc1)NO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC2 Q92769 9/20 1.00
▸ HDAC3 O15379 9/20 1.00
▸ HDAC1 Q13547 9/20 1.00
▸ HDAC8 Q9BY41 8/20 1.00
▸ HDAC4 P56524 7/20 1.00
▸ HDAC6 Q9UBN7 7/20 1.00
▸ HDAC7 Q8WUI4 6/20 0.74
▸ HDAC10 Q969S8 6/20 0.74
▸ HDAC11 Q96DB2 6/20 0.74
▸ HDAC9 Q9UKV0 6/20 0.74
▸ HDAC5 Q9UQL6 6/20 0.74
▸ EGFR P00533 3/20 0.68
▸ MMP1 P03956 2/20 0.68
▸ MMP2 P08253 2/20 0.68
▸ MMP9 P14780 2/20 0.68
▸ MAOA P21397 1/20 0.68
▸ MAOB P27338 1/20 0.68
▸ TNKS O95271 1/20 0.64
▸ HCAR2 Q8TDS4 1/20 0.64
▸ TNKS2 Q9H2K2 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1325253 1.00 HDAC2 (1.00) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL3292226 0.88 HDAC2 (1.00) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL3290139 0.88 HDAC2 (1.00) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL12120596 0.87 HDAC2 (0.90) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL11704209 0.86 HDAC3 (0.76) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL11704206 0.86 HDAC3 (0.76) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL4029206 0.86 HDAC2 (0.76) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL29060766 0.86 HDAC2 (0.76) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL25118498 0.85 HDAC1 (0.72) HDAC2HDAC3HDAC1HDAC8HDAC4
SCHEMBL6882499 0.85 HDAC4 (1.00) HDAC2HDAC3HDAC1HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264047-A Quinoline derivative histone deacetylase inhibitor and preparation method and application thereof 山东大学 2025-01-07 — — CN claimed
CN-117142983-A Oxime cinnamate compound, preparation method and application 西北农林科技大学 2023-12-01 — — CN claimed
US-20220133892-A1 Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions UNIV EMORY (US) 2022-05-05 — — US claimed
EP-3930746-A1 CHIMERIC COMPOUNDS AND METHODS OF MANAGING NEUROLOGICAL DISORDERS OR CONDITIONS Emory University (US) 2022-01-05 — — EP claimed
WO-2021115188-A1 HISTONE DEACETYLASE, AND PROTEASOME DUAL-TARGET INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 山东大学 2021-06-17 — — WO claimed
CN-110950897-A Histone deacetylase, protease double-target inhibitor, preparation method and application thereof 山东大学 2020-04-03 — — CN claimed
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC 2011-11-24 — — US claimed
WO-2008011074-A2 HISTONE DEACETYLASE INHIBITORS ERRANT GENE THERAPEUTICS, LLC (US) 2008-01-24 — — WO claimed
US-7312247-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2007-12-25 — — US claimed
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid ERRANT GENE THERAPEUTICS, LLC 2007-02-15 — — US claimed
EP-1408946-A4 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2004-06-09 — — EP claimed
EP-1408946-A2 HISTONE DEACETYLASE INHIBITORS Circagen Pharmaceutical (US) 2004-04-21 — — EP claimed
US-20020143052-A1 Histone deacetylase inhibitors ANGELA CHEN SABELLA 2002-10-03 — — US claimed
WO-2002076941-A2 HISTONE DEACETYLASE INHIBITORS CIRCAGEN PHARMACEUTICAL (US) 2002-10-03 — — WO claimed
JP-6293724-A — — None — — JP disclosed
US-12582719-B2 Chimeric compounds and methods of managing neurological disorders or conditions EMORY UNIVERSITY (US) 2026-03-24 — — US disclosed
CN-120157555-A Preparation method of primary amide compound 浙江工业大学 2025-06-17 — — CN disclosed
US-5424480-A Fungicides HOECHST AKTIENGESELLSCHAFT (DE) 1995-06-13 — — US disclosed
US-5424480-A Fungicides HOECHST AKTIENGESELLSCHAFT (DE) 1995-06-13 — — US disclosed
JP-H06293724-A SUBSTITUTED N-HYDROXYCINNAMAMIDE, ITS PREPARATION, COMPOSITION CONTAINING IT AND ITS USE HOECHST AG 1994-10-21 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143052-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC9 HDAC2 8/4885HDAC3 7/4885HDAC1 1/4885
US-20220133892-A1 Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions MAOA, HNMT, HDAC6 HDAC2 34/4885HDAC3 46/4885HDAC1 12/4885
US-20110288168-A1 HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC6, HDAC5 HDAC2 11/4885HDAC3 6/4885HDAC1 1/4885
US-12582719-B2 Chimeric compounds and methods of managing neurological disorders or conditions SLC6A4, HTR4, HTR1A HDAC2 131/4885HDAC3 153/4885HDAC1 101/4885
US-20070037869-A1 Treating spinal muscular atrophy with an effective amount of carboxylic acid derivative or hydroxamic acid derivative compound; treating cancer, blood disorders, genetic related metabolic disorders; 5-phenyl-2,4-pentadienoic acid HDAC5, HDAC1, ZNF277 HDAC2 9/4885HDAC3 7/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.